Teva to advance vitiligo antibody TEV-'408 into Phase 2b trials

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. NOW
3. TSLA
4. TXN
5. GOOG
6. IBM
7. KNX
8. LVS
9. INTC
10. ACI

Go back to Teva to advance vitiligo antibody TEV-'408 into Phase 2b trials
TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) Delayed: 30.15 --0 (-0%)
Previous Close $30.15    52 Week High $66.55 
Open $30.15    52 Week Low $37.82 
Day High $30.15    P/E N/A 
Day Low $30.15    EPS $0.00 
Volume 2,399